https://www.selleckchem.com/pr....oducts/lomerizine-hc
Early treatment of patients at risk for developing aggressive prostate cancer is able to delay metastasis and reduce mortality; as such, up-front identification of these patients is critical. Several risk classification systems, including CAPRA-S, are currently used for disease prognostication. However, high-risk patients identified by these systems can still exhibit wide-ranging disease outcomes, leading to overtreatment of some patients in this group. The master methylation regulator TET2 is downregulated in prostate cancer, wh
お気に入り
コメント
シェア
